GeneralBearishBlockonomi · 2h ago6/10
📰
Abivax (ABVX) Stock Plunges 32% Despite Breakthrough Trial Results
Abivax (ABVX) experienced a severe 32% stock decline despite achieving positive Phase 3 trial results, as safety concerns emerged from rare cancer cases among trial participants that prompted analyst downgrades. The disconnect between clinical efficacy and market reaction underscores how safety signals can override positive efficacy data in biotech valuations.